PubMed Health⌕ Search

Biomedical subjects

B I Milcarek

Publications and source records attributed to B I Milcarek.

3 recordsLinked to original sources

A retrospective cohort mortality study of blending and packaging workers of Mobil Corporation.

This retrospective cohort mortality study examined 2,467 workers in lubrication products blending and packaging (B&P) operations at two refineries of Mobil Corporation between January 1, 1945 and December 31, 1978. Ninety-seven percent were male. Compared with U.S. males, there were significantly fewer deaths observed among males due to all causes, external causes, and diseases of the circulatory, respiratory, digestive, and genitourinary systems. Deaths observed from all cancer were fewer than expected, although not statistically significant. No statistically significant excess cause-specific mortality occurred at B&P facilities combined or separately. Nonsignificant increases in mortality were observed for cancers of the stomach, large intestine, prostate, the category of "other lymphatic tissue" cancer, and leukemia and aleukemia. Analyses demonstrated a statistically significant pattern of increasing SMR with employment duration for "other lymphatic tissue" cancer. Within the highest cumulative duration of employment category, the excess was confined to workers after 30 or more years since first employment. Although the interpretation of cancer mortality patterns is limited due to small numbers of deaths, the absence of associations with specific B&P departments is evidence against a causal interpretation.

Aged↗

Diazepam: how much better than placebo?

In a six week, double-blind, predictive, clinical study 224 neurotic and anxious outpatients were randomly assigned to treatment with diazepam (Valium) of placebo and weekly brief psychotherapy administered by experienced psychiatrists. Although diazepam was significantly more effective than placebo for the first week of treatment, it accounted for only 1-4% of the outcome variance, while nonspecific variables contributed 11-22%. After the first revisit and at endpoint, only nonspecific variables accounted for outcome variance ranging from 20 to 26% over the four outcome measures. According to physicians' global and scaled ratings of improvement, diazepam had a treatment advantage (p less than 0.01-0.05) over placebo at the end of the first week of treatment for both the total and completed samples, but not thereafter. According to patients' global ratings of improvement, diazepam was moderately superior (p less than 0.05) to placebo for the total sample only at the end of the first week of treatment and modestly better (p less than 0.10) than placebo for the completed sample on a highly reliable measure of reported anxiety at the same time point. However, patient ratings did not indicate an advantage for diazepam at any of the six points of observation on global ratings of improvement for the completed sample and on reported anxiety for the total sample.

Adult↗